Abstract
Efficacy of intravenous midazolam was evaluated in 97 children (1 month to 16 years of age) with status epilepticus (108 seizure episodes) from 1996 to 2004. The etiologies of 108 seizure episodes were as follows: epilepsy in 50, febrile convulsion (FC) in 37, and acute encephalopathy/encephalitis in 10. In epilepsy group, the duration of status epilepticus was significantly short in patients with midazolam treatment compared with those without midazolam administration. And the rate of seizure cessation was significantly higher in patients with midazolam than those with diazepam treatment in epilepsy group. Adverse effects of midazolam were recognized in only one patient showing transient hypoxemia, but mechanical ventilation was not required. Considering these results, it is suggested that intravenous midazolam is efficacious and safe treatment for status epilepticus in children.
